Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation

Mo et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69d98391a1d151c65f684669 — DOI: https://doi.org/10.1001/jamaoncol.2023.0425

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial· 2018 · 67 citations
2. Effect of Adjuvant Chemotherapy on Survival of Elderly Patients With Stage III Colorectal Cancer· 2021 · 9 citations
3. Circulating mutant DNA to assess tumor dynamics· 2008 · 2,708 citations
4. Predictive Value of Preoperative Carcinoembryonic Antigen Levels for the Prognosis of Patients with Well-Differentiated Gastric Cancer· 2009 · 33 citations
5. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to <i>BRAF</i> Mutation and Mismatch Repair Status of the MOSAIC Study· 2015 · 671 citations